Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases
- First Online:
- Cite this article as:
- Sengler, C., Niewerth, M., Kallinich, T. et al. Clin Rheumatol (2014) 33: 137. doi:10.1007/s10067-013-2435-8
- 130 Downloads
The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented—38 % under treatment with biologicals—of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.